SCHEMBL4347461

SCHEMBL4347461

O=C(Nc1ccc(Oc2ccccc2)cc1)Nc1cccc(F)c1O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.59
RAB9A P51151 5/20 0.59
SMN1; SMN2 Q16637 5/20 0.59
NFKB1 P19838 2/20 0.59
NFKB2 Q00653 2/20 0.59
RELA Q04206 2/20 0.59
PKM P14618 2/20 0.59
KMT2A Q03164 4/20 0.58
MEN1 O00255 3/20 0.58
MAPT P10636 3/20 0.58
LMNA P02545 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
HTT P42858 3/20 0.55
POLB P06746 1/20 0.55
FAAH O00519 1/20 0.54
CA12 O43570 5/20 0.53
CA1 P00915 5/20 0.53
CA2 P00918 5/20 0.53
CA9 Q16790 5/20 0.53
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348999 0.87 KMT2A (0.70) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL6228091 0.84 EPHX2 (0.71)
SCHEMBL4345603 0.84 CA12 (0.54) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL4347494 0.84 MEN1 (0.74) NPC1RAB9ASMN1; SMN2KMT2AMEN1
SCHEMBL4356007 0.83 EPHX2 (0.66) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL4348975 0.82 NPC1 (0.55) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL4346263 0.82 CA12 (0.56) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL6673220 0.81 CA12 (0.55) SMN1; SMN2KMT2AMEN1MAPTLMNA
SCHEMBL30053559 0.81 CA12 (0.73) NPC1RAB9ASMN1; SMN2PKMKMT2A
SCHEMBL4346986 0.80 NPC1 (0.56) NPC1RAB9ASMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 NPC1 815/4885RAB9A 4228/4885SMN1; SMN2 1791/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 NPC1 1189/4885RAB9A 4588/4885SMN1; SMN2 3250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.